Xeris Biopharma Holdings annual free cash flow
2020
2021
Xeris Biopharma Holdings Free Cash Flow (FCF) History (XERS)
Xeris Biopharma Holdings reported −$96.6M in free cash flow for fiscal 2021, a decrease of $15.7M from the previous fiscal year, with a free cash flow margin of −194.84%.
View full Xeris Biopharma Holdings company overviewXeris Biopharma Holdings free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2021 | 2021-12-31 | −$96.6M | −$15.7M | — | −194.84% |
| 2020 | 2020-12-31 | −$80.9M | — | — | −401.56% |
Xeris Biopharma Holdings quarterly free cash flow
No reported data
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|
Xeris Biopharma Holdings free cash flow growth trends
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Xeris Biopharma Holdings filings at SEC.gov ↗